Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Up 0.6% – Here’s What Happened

Posted by ABMN Staff on Dec 24th, 2024

Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) traded up 0.6% during trading on Monday . The stock traded as high as $3.36 and last traded at $3.29. 33,873 shares were traded during trading, a decline of 52% from the average session volume of 70,291 shares. The stock had previously closed at $3.27.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Kiora Pharmaceuticals in a report on Tuesday, November 12th.

Read Our Latest Stock Report on Kiora Pharmaceuticals

Kiora Pharmaceuticals Stock Performance

The firm has a 50 day simple moving average of $3.48 and a 200 day simple moving average of $4.04.

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities research analysts anticipate that Kiora Pharmaceuticals, Inc. will post 0.89 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing. 76.97% of the stock is owned by hedge funds and other institutional investors.

About Kiora Pharmaceuticals

(Get Free Report)

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.